Clinical Trial: Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics

U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07748364) titled 'Glofitamab in B-NHL Using Mid-Therapy Intratumoral Transcriptomics' on July 31.

Brief Summary: This trial will enroll patients with relapsed/refractory DLBCL and MCL, with the opportunity to receive single-agent glofitamab as early as the second-line. Patients will have superficially accessible disease to enable core-needle biopsy prior to therapy initiation, and on cycle 1 day 15 and cycle 2 day 1 of therapy administration to enable high throughput molecular profiling of disease and immune dynamics while on treatment.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Relapsed/Refractory Diffuse Large B-cell Lym...